Intrapleural Administration of HSV1716 to Treat Patients With Malignant Ple... | Completed
Intrapleural Administration of HSV1... | Completed
Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
1716-12

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Malignant Pleural Mesothelioma
Primary Contact Details
Unfortunately contact details are not available for this trial.
Recruitment Status
Completed
Trial source and source ID number
NCT01721018

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
HSV1716, an oncolytic virus, is a mutant herpes simplex virus (HSV) type I, deleted in the RL1 gene which encodes the protein ICP34.5.

Malignant mesothelioma is an aggressive, asbestos-related tumour of the pleural and peritoneal cavities. It is a rare cancer which occurs in individuals who have been exposed to asbestos, although it typically occurs decades after exposure (10-40 years later). Malignant pleural mesothelioma forms plaques that are distributed on the surface of the pleural space in the lung. Approximately 30% of patients require an indwelling pleural catheter for drainage of pleural effusions. In this patient group, the indwelling catheter may be used to facilitate loco-regional delivery of HSV1716 to the pleural space.

This study seeks to evaluate the safety and biological effects of single and multiple administrations of HSV1716 in the treatment of malignant pleural mesothelioma.
Research Details
  • The study will be conducted in two parts. PART A is a single centre, single dose design, open label. Patients with inoperable malignant pleural mesothelioma will receive a single dose of HSV1716 by intrapleural administration. Delivery will be by direct administration via an indwelling catheter into the pleural cavity. PART B is a single centre, repeat dose design, open label. Two groups of three patients with inoperable malignant pleural mesothelioma will receive 2 (group 1) or 4 (group 2) single doses of HSV1716 at weekly intervals. Administration will be via an indwelling catheter into the pleural cavity.
Phase
Phase 1/Phase 2
Study Design
Sorry, this information is not available
Study Type
Interventional
Intervention
Biological : HSV1716 Intra-pleural delivery

Study Arm Groups : HSV1716

Intervention Type
See Interventions above
Primary Outcome Measures
    Safety and tolerability of HSV1716 given by single and repeat intrapleural administration in patients with inoperable malignant pleural mesothelioma.; Dose limiting toxicities will be assessed at 28 days after last injection of HSV1716.
Secondary Outcome Measures
    Obtain evidence of HSV1716 replication and lysis of malignant pleural mesothelioma cells through analysis of pleural fluid and serum samples for evidence of cell death and/or HSV1716 replication and/or changes in appropriate biomarkers.; Samples will be collected at each outpatient visit up to day 29 (Part A), or day 50 (Part B).
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
All
Age Range
18 Years - N/A
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
    Inclusion Criteria:

    - Patients with histologically proven malignant pleural mesothelioma

    - Patients with disease which is not amenable to potentially curative resection

    - Patients with pleural effusions and/or 'trapped lung' who (i) have an existing indwelling pleural catheter for draining of excess pleural fluid or (ii) who require the insertion of an indwelling pleural catheter to drain excess pleural fluid

    - Patients with a performance status ≤ 2 (ECOG)

    - Age of ≥ 18 years (at screening)

    - Ability to give written informed consent as evidenced by signature on the patient consent form, to communicate well with the investigator and to comply with the expectations of the study

    Exclusion Criteria:

    - Patients likely to require palliative radio- or chemotherapy within 30 days

    - Any evidence of uncontrolled cardiac or respiratory disease that would be a contra-indication for virus administration

    - Any other serious medical or psychiatric disorder that would be a contra-indication for virus administration

    - Acute active infection of any kind or other severe systemic disease or medical or surgical condition that is deemed significant by the principal investigator

    - Patients with immunosuppressive disorders or on systemic steroids > 5mg prednisolone/day

    - Pregnancy: women of childbearing potential not taking adequate contraception, and women who are breast feeding

    - Previous treatment with investigational viral therapy products

    - Administration of any unlicensed or investigational product within 8 weeks of entry to the study

    - No prior or concurrent malignancy within 5 years other than basal cell carcinoma of the skin or in situ neoplasia of the cervix uteri

    - Inadequate haematological function as defined by:

    Haemoglobin (Hb) < 10g/dl, Neutrophil Count < 1.5 x 10e9/l, Platelets < 100 x 10e9/l

    - Deranged liver function tests: serum bilirubin ≥ 1.5 x upper limit of normal reference range for laboratory; transaminases ≥ 5 x upper limit of normal reference range

    - Patients with inadequate renal function: serum creatinine ≥ 1.5 x upper limit of reference range for laboratory

    - Patients whose indwelling catheter is not of the type approved by the sponsor for use in the study

    - Outwith any of the inclusion criteria above or considered unsuitable for entry into the study in any other way at the discretion of the principal investigator
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Southern General Hospital
Glasgow
Scotland
G51 4TF
Sheffield
S10 2SJ
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma.
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
1716-12
Sponsor(s)
Virttu Biologics Limited
Key Dates

Recruitment Start Date

Oct 2012

Recruitment End Date

Nov 2016

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

22 Oct 2012

Date updated in source

08 Jun 2017